

CURRICULUM VITAE

ALEXIS ANNE THOMPSON

Home Address:

[REDACTED]
[REDACTED]
[REDACTED]

Office Address:

Department of Pediatrics
Division of Hematology
Children's Hospital of Philadelphia
3401 Civic Center Blvd
Philadelphia, PA 19104
(215) 590-2363
[REDACTED]

Education:

1976-79 Pomona College (Zoology)
1979-83 M.D., Tulane University School of Medicine
1986-87 M.P.H., University of California, Los Angeles (Health Services)

Postgraduate Training and Fellowship Appointments:

07/1983-06/84 Intern in Pediatrics, Children's Hospital of Los Angeles
07/1984-06/86 Resident in Pediatrics, Children's Hospital of Los Angeles
07/1987-06/90 Fellow, Pediatric Hematology/Oncology, Children's Hospital of Philadelphia

Hospital and Administrative Appointments

07/1987-06/90 Instructor in Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine (Pennsylvania)
07/1990-06/92 Clinical Instructor, Pediatric Hematology/Oncology, University of California, Los Angeles (UCLA) School of Medicine (California)
07/1992-06/99 Assistant Professor, Department of Pediatrics, UCLA School of Medicine (California)
07/1999-06/2000 Associate Professor, Department of Pediatrics, UCLA School of Medicine (California)
04/2001-06/10 Associate Professor, Department of Pediatrics, Feinberg School of Medicine, Northwestern University (Illinois)
07/2011-12/21 Professor, Department of Pediatrics, Feinberg School of Medicine, Northwestern University (Illinois)
01/2022-present Professor, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania (Pennsylvania)

Employment with Hands on Patient Contact

07/1990-12/2000 UCLA School of Medicine (California)
01/2001-04/01 not employed (vacation)

04/2001-12/2021 Children's Memorial/Lurie Children's Hospital (Illinois)
01/2023-present Children's Hospital of Philadelphia (Pennsylvania)

Specialty Certification:

1986 General Pediatrics, No. 35644
1990 Pediatric Hematology/Oncology, No. 948 (Recertification, 2021)

Licensure:

California, No. G53158 (inactive)
Illinois, No. 036-104288
Pennsylvania No. MD039064E

Awards and Honors:

1983 Henry J. Kaiser Family Foundation Merit Scholarship Award
1983 Carl Robinson, Jr Outstanding Senior Medical Student
1987 Kaiser Permanente Merit Scholarship Award in Health Services
1992-96 Robert Wood Johnson Foundation Minority Medical Faculty Development Award
1994 R55, James A. Shannon Director's Award
1997 STOP Cancer: The Next Generation Award
1997 Minority Scholar Award in Cancer Research, American Association for Cancer Research (AACR)
1998 Young Investigator Research Award, Orange County Roosters
2001- Sarah and A. Watson Armour Endowed Chair for Blood Diseases and Cancer, Children's Memorial Hospital
2015 Erslev Memorial Lecture, Jefferson Medical College, Philadelphia, PA
2017 Frank A. Oski Memorial Lecture and Award, American Society of Pediatric Hematology Oncology (ASPHO)
2018 Alpha Omega Alpha National Medical Honor Society (faculty inductee)
2018 William C. Moloney Lecture, Brigham and Women's Hospital, Boston MA
2018 Paul M. Aggeler Lecture, UCSF/ZSFGH, San Francisco, CA
2019 Gwynne Hazen Cherry Family/Stephen A. Feig, M.D. Endowed Lecturer, UCLA Mattel Children's Hospital
2019 Alexander S. Weiner Memorial Lecture, New York Blood Center
2019 Faculty Excellence in Leadership Award, Lurie Children's Hospital (inaugural recipient)
2020 Top Blacks in Healthcare, blackdoctors.org
Distinguished Alumni Award, Champions of Healthcare, National Medical Fellowships
Cage S. Johnson, Sickle Cell Physician Award, Cayenne Wellness
2021 Exceptional Women in Medicine, *Chicago Magazine*
2022 Fellow, College of Physicians of Philadelphia

Membership in Professional and Scientific Societies:

American Society of Hematology
National Medical Association

American Society of Pediatric Hematology-Oncology
American Society of Genetic and Cell Therapy
European Hematology Association

Professional Activities:

1992 Investigator, Zimbabwe Community Health Care Development Project
1994-96 Member, Minority Advisory Panel, National Marrow Donor Program
1996-00 Member, Minority Affairs Committee, National Marrow Donor Program
1996-00 Consultant, California State Newborn Screening Program
1997-04 Program Development Committee, Fellowship Program in Academic Medicine, Bristol Myers Squibb-National Medical Fellowship (Chair, 2002-04)
1997-01 Director, UCLA Sickle Cell Anemia Program
1999-00 Medical Advisory Board, Sickle Cell Disease Research Foundation
2000-04 Board of Directors, National Marrow Donor Program
2001-04 Executive Committee, Board of Directors, National Marrow Donor Program
2001-05 Eligibility Review Panel, Sibling Donor Cord Blood Transplant Study for Hemoglobinopathies, NHLBI
2001-21 Medical and Scientific Director of Hematology, Children's Memorial Hospital
2001-02 Ad Hoc Reviewer, BMT Clinical Trials Network, NHLBI
2003- Medical Advisory Board, Cooley's Anemia Foundation
2003-07 Ad Hoc Minority Committee, American Society of Hematology
2003-07 President, E. E. Just Society
2006 Diamond-Blackfan Anemia Advisory Working Group, CDC
2006-10 Eligibility Review Panel, Unrelated Stem Cell Transplant Study for Sickle Cell, BMT Clinical Trials Network
2006-09 Clinical Trials Review Committee, NHLBI
2006-12 Government Affairs Committee, American Society of Hematology (ASH)
2007-09 Co-Chair, Education Program, 2009 Annual ASH Meeting
2008-16 Genetic and Metabolic Diseases Advisory Committee, Illinois Dept. of Public Health
2008-21 Associate Director, Equity and Minority Health, Robert H. Lurie Comprehensive Cancer Center, Northwestern University
2009 Healthy People 2020, Hemoglobinopathies Working Group, Objectives for Blood Disorders and Blood Safety (BDBS), Department of Health and Human Services
2009- Sickle Cell Disease Task Force, American Society of Hematology
2009 Co-Chair, Highlights of ASH 2010 (Domestic)
2009 Co-Chair, Highlights of ASH 2010 in Latin America
2009-11 Sickle Cell Disease Advisory Committee, NHLBI
2010-14 Councilor, Executive Committee, American Society of Hematology
2011-16 Secretary's Advisory Committee on Heritable Disorders in Newborns and Children, Department of Health and Human Services
2011-14 American Cancer Society-Illinois Division Cancer Disparities Research Task Force
2012-15 Co-Chair, Interventional Committee, Pediatric ITP Consortium of North America
2013-15 Ad Hoc reviewer, K-award study section, NHLBI
2015-16 Vice President, American Society of Hematology

2016-17 President-Elect, American Society of Hematology
 2018 President, American Society of Hematology
 2018-22 Member, Steering Committee, Cure Sickle Cell Initiative, NHLBI
 2018-21 Chair, Clinical Trials Design Subcommittee, Cure Sickle Cell Initiative
 2021- European Hematology Association
 2022- Member, OSMB, COALESCE Study, NHLBI
 2022- Member, Board of Scientific Counselors, NHLBI

Journal Reviewer:

1992- Reviewer, Journal of Pediatric Hematology-Oncology
 1995- Reviewer, BLOOD
 1995-00 Reviewer, International Journal of Pediatric Hematology Oncology
 2002- Reviewer, Haematologica
 2005- Reviewer, Pediatric Blood and Cancer
 2007- Reviewer, New England Journal of Medicine
 2015- Reviewer, Blood Advances
 2019- Reviewer, Science Translational Medicine
 2021-24 Editorial Board, BLOOD

Hospital and Academic Committees:

1991-00 Admissions Committee, UCLA School of Medicine
 1991-00 Medical School Alumni Association, Subcommittee on Minority Recruitment
 1999-00 Executive Board, Department of Pediatrics Group Practice
 1998-00 Medical Center Cancer Committee
 2000 Medical Center Blood and Blood Derivatives Committee
 2002-04 Best Practices Guidelines on Sickle Cell Pain Committee
 2003-12 Library Committee, Children's Memorial Research Center
 2004-06 Best Practices on the Utilization of Recombinant Factor VIIa Committee
 2004 Departmental Diversity Task Force, Children's Memorial Hospital
 2005-06 Safety Quality Leadership Team, Timely Evaluation Task Force
 2008-13 Cancer and Blood Disorders Committee, Children's Memorial Hospital
 2010-18 Advisory Board, Northwestern Medicine (NM) Scholars Program at Westinghouse College Prep
 2011-18 Anticoagulation Safety Committee (co-Chair)
 2014-21 Faculty Coach, Office of Faculty Development, Department of Pediatrics
 2015-21 Diversity and Inclusion Council, Northwestern University Feinberg School of Medicine
 2020 Vaccine Equity Taskforce, Lurie Children's
 URiM Pediatric Residency Recruitment Spotlight Panelist, Lurie Children's
 2021 Executive Leadership Committee, Institutional KL2 Program, Northwestern University Clinical and Translational Science Institute (NUCATS)
 Internal Advisory Committee, Chicago Cancer Health Equity Council
 Educational Diversity, Equity and Inclusion Council, Lurie Children's
 2022- Executive Committee, Department of Pediatrics, Children's Hospital of Philadelphia (CHOP)
 Executive Committee, Cell and Gene Therapy Collaborative, CHOP

Current clinical/research interests:

- Management of patients with sickle cell disease and other hemoglobinopathies
- Bone marrow failure syndromes
- Stem cell transplantation for nonmalignant disorders in pediatric patients

Publications:Co-Editor

Hematology 2009 American Society of Hematology Education Program

Section Editor

“Disorders of the Blood and Blood Cells.” Just the Facts in Pediatrics, MacGraw Hill, 2004

Author, Book Chapters

Thompson AA: “Anemia Overview,” Just the Facts in Pediatrics, MacGraw Hill, 2004

Thompson AA: “Thalassemias” Just the Facts in Pediatrics, MacGraw Hill, 2004

Thompson AA: “Neutropenias,” Just the Facts in Pediatrics, MacGraw Hill, 2004

MacDonald L and Thompson AA: “Iron Deficiency Anemia,” Just the Facts in Pediatrics, MacGraw Hill, 2004

Gosiengfiao Y and Thompson AA: “Hemolytic Anemias,” Just the Facts in Pediatrics, MacGraw Hill, 2004

Weinstein J and Thompson AA: “Thrombocytopenia,” Just the Facts in Pediatrics, MacGraw Hill, 2004

Badawy SM, Thompson AA: “Management Challenges in Thalassemia” from Abutalib SA, Connors JM, Ragni MV (eds) (2016) Nonmalignant Hematology, Expert Clinical Review: Questions and Answer, Springer International Publishing, Switzerland

Peer-reviewed Manuscripts

1. Wood WJ, Thompson AA, Korenberg J, May WA, Denny CT, Wall R: The Isolation and Chromosomal Mapping of the Human Immunoglobulin-Associated B29 Gene. Genomics 16: 187-192, 1993. PMID 8486355
2. May W, Korenberg J, Chen X-n, Wood WJ, Thompson AA, Wall R, Denny CT: Human Lymphocyte-Specific Gene pp52 is a Member of a Highly Dispersed Gene Family. Genomics 15: 515-520, 1993. PMID 8468046
3. Thompson AA, Cornelius AS, Asakura T, Horiuchi K: Comparative Studies of Phenothiazine Derivatives and Their Effects on Swelling of Normal and Sickle Erythrocytes. Gen Pharmacol. 24 (4): 999-1006, 1993. PMID 7901117
4. Thompson AA, Wood WJ, Gilly MJ, Omori SA, Wall R: The Promoter and 5' Flanking Sequences Controlling Human B29 Gene Expression. Blood 87: 666-673, 1996.
5. Thompson AA, Omori SA, Gilly MJ, May W, Gordon MS, Wood WJ, Miyoshi E, Malone CS, Gimble J, Kincade P, Denny CT, Wall R: Structure of Alternatively Spliced 5' Exons in Tissue-Specific Isoforms of Leukocyte pp52 and Stromal Cell S37 mRNA. Genomics 32: 352-357, 1996.
6. Thompson AA, Talley JA, Do HN, Saxon A, Kunkel L, Berenson J, Wall R: Aberrations of the B-cell Receptor B29 Gene Expression in Chronic Lymphocytic Leukemia. Blood 90 (4): 1387-1394, 1997.

7. Thompson AA, Do HN, Saxon A, Wall R: Widespread B29 (CD79b) Gene Defects and Loss of Expression in Chronic Lymphocytic Leukemia. *Leukemia and Lymphoma* 32 (5-6): 561-569, 1999. PMID 10048429
8. Gordon MS, Kato RM, Lansigan F, Thompson AA, Wall R, Rawlings DJ: Aberrant BCR Signaling from B29 (Ig β , CD79b) Gene Mutations of Chronic Lymphocytic Leukemia B Cells. *Proc Natl Acad Sci* 97 (10):5504-09, 2000. PMID 10792036
9. Thompson AA, Nguyen LT: Amegakaryocytic Thrombocytopenia and Radial-Ulnar Synostosis is Associated with a *HOXA11* Gene Defect. *Nature Genetics* 26 (4): 379-80, 2000.
10. Miyoshi E, Stewart PL, Kincade PW, Lee MB, Thompson AA, Wall R: Aberrant Expression and Localization of the Cytoskeleton-Binding pp52 (LSP1) Protein in Hairy Cell Leukemia. *Leukemia Research* 25: 57-67, 2001.
11. Thompson AA, Woodruff K, Feig SA, Nguyen LT, Schanen NC: Congenital Thrombocytopenia and Radio-Ulnar Synostosis: A New Familial Syndrome. *British Journal of Haematology* 113(4): 866-70, 2001.
12. Barcelona SL, Thompson AA, Cote CJ: Intraoperative Pediatric Blood Transfusion Therapy: A Review of Common Issues. Part I: Hematologic and Physiologic Differences from Adults; Metabolic and Infectious Risks. *Pediatric Anesthesia* 15 (9): 716-26, 2005.
13. Barcelona SL, Thompson AA, Cote CJ: Intraoperative Pediatric Blood Transfusion Therapy: A Review of Common Issues. Part II: Transfusion Therapy, Special Considerations, and Reduction of Allogenic Blood Transfusions. *Pediatric Anesthesia*. 15 (10): 814-30, 2005.
14. Thompson AA: Advances in the Management of Sickle Cell Disease. *Pediatric Blood and Cancer* 46 (5): 533-39, 2006.
15. Horvat R, Thompson AA: *HOXA11* Mutation in Amegakaryocytic Thrombocytopenia with Radio-Ulnar Synostosis Syndrome Inhibits Megakaryocytic Differentiation In Vitro. *Blood Cells Molecules and Disease* 37 (1): 55-63, 2006.
16. Storey P, Thompson AA, Carqueville CL, Wood JC, Rigsby CK: R2* Imaging of Transfusional Iron Burden at 3T and Comparison with 1.5T. *J Magnetic Resonance Imaging* 25: 540-7, 2007.
17. Eggleston BS, Patience M, Edwards S, Adamkiewicz T, Buchanan G, Davies SC, Dickerhoff R, Donfield S, Feig SA, Giller RH, Haight A, Horan J, Hsu L, Kamani N, Lane P, Levine JE, Margolis D, Moore TB, Ohene-Frempong K, Redding-Lallinger R, Roberts IAG, Rogers ZR, Sanders JE, Scott JP, Sleight B, Thompson AA, Sullivan KM, Walters MC: Effect of Myeloablative Bone Marrow Transplantation on Growth in Children with Sickle Cell Anemia: Results of the Multicenter Study of Hematopoietic Cell Transplantation for Sickle Cell Anemia. *British Journal of Haematology*. 136 (4): 673-6, 2007.
18. Gosiengfiao Y, Horvat R, Thompson AA: Transcription Factors GATA-1 and Fli-1 Regulate Human HOXA10 Expression in Megakaryocytic Cells, *DNA and Cell Biology*, 26(8): 577-87, 2007.
19. MJ Manco-Johnson, TC. Abshire, AD Shapiro, B Riske, MR Hacker, R Kilcoyne, D Ingram, ML Manco-Johnson, S Funk, L Jacobson, L A. Valentino, WK Hoots, GR. Buchanan, D DiMichele, M Recht, D Brown, C Leisinger, S Bleak, A Cohen, P Mathew, A Matsunaga, D Medeiros, D Nugent, G Thomas, AA Thompson, JM Soucie, H Austin,

- and B Evatt: Results of a Prospective, Controlled, Randomized Clinical Trial to Prevent Joint Disease in Young Children with Severe Factor VIII Deficiency, *New England Journal of Medicine*, 357(6):535-44, 2007.
20. Liem, RI, Young L, Thompson AA: Tricuspid Regurgitant Jet Velocity Is Associated with Hemolysis in Children and Young Adults with Sickle Cell Disease Evaluated for Pulmonary Hypertension, *Haematologica*, 92, 1549-52, 2007
 21. Liem RI, Calamaras D, Chhabra-Singh M, Minniti C, Files B, Thompson AA: Sudden-onset blindness in sickle cell disease due to retinal artery occlusion. *Pediatric Blood & Cancer*. 50(3):624-7, 2008.
 22. Fung EB, Harmatz P, Milet M, Coates T, Thompson AA, Ranalli M, Mignaca R, Scher C, Giardina P, Robertson S, Neumayr L, Vichinsky E: Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. *Bone* 43, 162-68, 2008.
 23. Liem RI, Nevin MA, Young LT, Thompson AA: Tricuspid regurgitant jet velocity elevation and its relationship to lung function in pediatric sickle cell disease. *Pediatric Pulmonology* 44(3): 281-9, 2009
 24. Liem RI, Young LT, Thompson AA: Prolonged QTc interval in children and young adults with sickle cell disease at steady state. *Pediatric Blood Cancer*. Jul;52(7):842-6, 2009.
 25. Liem RI, Nevin MA, Prestridge A, Young LT, Thompson AA: Functional capacity in children and young adults with sickle cell disease undergoing evaluation for cardiopulmonary disease. *Am J Hematol*. 2Liem RI, Cole AH, Pelligra SA, Mason M, Thompson AA: Parental attitudes toward research participation in pediatric sickle cell disease. *Pediatric Blood & Cancer* 55(1):129, 2010
 27. Lulla RR, Thompson AA, Liem RI: Elevated soluble transferrin receptor reflects increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease. *Pediatric Blood & Cancer* 55(1):141, 2010.
 28. Trachtenberg F, Foote D, Martin M, Carson S, Coates T, Beams O, Vega O, Merelles-Pulcini M, Giardina PJ, Kleinert DA, Kwiatkowski J, Thompson AA, Neufeld EJ, Schilling L, Thayalasuthan V, Pakbaz Z, Yamashita R: Pain as an emergent issue in thalassemia. *Am J Hematol* May 2010 85(5): 367–370
 29. Wood J, Kang B, Thompson AA, Paley C, Giardina P, Harmatz P, Virkus J, Coates T: The effect of deferasirox on cardiac iron in thalassemia major; impact of total body iron stores. *Blood*, Jul 2010; 116: 537 - 543.
 30. Liem RI, Pelligra S, Shah AD, Labotka RJ, Young LT, Thompson AA: Reproducibility of Tricuspid Regurgitant Jet Velocity Measurements in Children and Young Adults with Sickle Cell Disease Undergoing Screening for Pulmonary Hypertension, *Am J Hematol*,
 31. Gallo AM, Wilkie D, Suarez M, Labotka R, Molokie R, Thompson A, Hershberger P, Johnson B: Reproductive decisions in people with sickle cell disease or sickle cell trait. *West J Nurs Res* Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. *Am J Hematol*. 2010 Oct; 85(10):818-9.
 33. Mednick L, Yu S, Trachtenberg F, Xu Y, Kleinert D, Giardina PJ, Kwiatkowski JL, Foote D, Thayalasuthan V, Porter JP, Thompson AA, Schilling L, Quinn CT, Neufeld EJ, Yamashita R: Symptoms of depression and anxiety in patients with thalassemia: Prevalence and correlates in the thalassemia longitudinal cohort. *Am J Hematol* Hulbert

- ML, McKinstry RC, Lacey JL, Moran CJ, Panepinto JA, Thompson AA, Sarnaik SA, Woods GA, Casella JF, Inusa B, Howard J, Kirkham F, Anie K, Mullin JE, Ichord R, Noetzel M, Yan Y, Rodeghier M, DeBaun MR: Silent cerebral infarcts occur despite regular blood transfusion therapy after first stroke in children with sickle cell disease. *Blood*, 2011 Jan, 117(3):772-779
- Vichinsky CE, Ohene-Frempong K, Thein RC, Lopes de Castro Lobo C, Inati A, Thompson AA, Smith-Whitley K, Kwiatkowski JL, Swerdlow PS, Porter JB, Marks PW: Transfusion and chelation practices in sickle cell disease: a regional perspective. *Pediatr Hematol Oncol*. 2011 Mar; 28(2):124-33.
36. Poulter EY, Truszkowski P, Thompson AA, Liem RI: Acute Chest Syndrome is Associated with History of Asthma in Hemoglobin SC Disease. *Pediatric Blood Cancer*, 2011 Aug;57(2):289-93.
37. Wood J, Glynos T, Thompson AA, Paley C, Giardina P, Harmatz P, Kang BP, Coates TD: Relationship between labile plasma iron, liver iron concentration, and cardiac response in a deferasirox monotherapy trial. *Haematologica*, 2011 96(6).
38. Thompson AA, Cunningham MJ, Singer ST, Neufeld EJ, Vichinsky E, Yamashita R, Giardina P, Kim H-Y, Trachtenberg F, Kwiatkowski JL: Red Cell Alloimmunization in a Diverse Population of Transfused Patients with Thalassemia. *Brit J Haematol*, 2011 Apr;153(1):121-8
39. Sobota A, Yamashita R, Xu Y, Trachtenberg F, Kohlbry P, Kleinert DA, Giardina PJ, Kwiatkowski JL, Foote D, Thayalasuthan V, Porter JB, Thompson AA, Schilling L, Quinn CT, Neufeld EJ: Quality of life in thalassemia: A comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms. *Am J Hematol* Iron chelation adherence to deferoxamine and deferasirox in thalassemia. *Am J Hematol* 2011 May;86(5):433-6.
41. Liem RL, Gilgour B, Pelligra SA, Mason M, Thompson AA: The Impact of Thalassemia on Southeast Asian and Asian Indian Families in the US: A Qualitative Study. *Ethnicity and Disease* 2011 Summer; 21(3):361-9.
42. Poulter EY, Truszkowski P, Thompson AA, Liem RI: Acute chest syndrome is associated with history of asthma in hemoglobin SC disease. *Pediatr Blood Cancer*. 2011 Aug;57(2)289-93.
43. Morris CR, Hae-Young K, Trachtenberg F, Wood J, Quinn CT, Sweeters N, Kwiatkowski JL, Thompson AA, Giardina PJ, Boudreaux J, Olivieri NF, Porter JB, Neufeld EJ, Vichinsky EP: Risks factors and mortality associated with an elevated tricuspid-regurgitant-jet-velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. *Blood*. 2011 Oct 6;118(14):3794-802.
44. Recognition and management of hemophilia emergencies. *Clin Pediatr Emerg Med*, 2011 Sep 1;12(3):224-232.
- Lebensburger JD, Debaun MR, Thompson AA: What is the evidence for using hydroxyurea for secondary stroke prevention? *Hematology Am Soc Hematol Educ Program*. 2011;2011:440-2.
46. Thompson AA: Primary prophylaxis in sickle cell disease: is it feasible? Is it effective? *Hematology Am Soc Hematol Educ Program*. 2011;2011:434-9.
47. Kwiatkowski JL, Kim H-Y, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter J, Coates T, Olivieri NF, Neufeld EJ: Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. *Blood* 2012 Mar 22;119(12):2746-53.

48. Grace RF, Bennett CM, Ritchey AK, Jeng M, Thornburg CD, Lambert MP, Neier M, Recht M, Kumar M, Blanchette V, Klaassen RJ, Buchanan GR, Kurth MH, Nugent DJ, Thompson AA, Stine K, Kalish LA, Neufeld EJ: Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. *Pediatr Blood Cancer*. 2012 Feb;58(2):221-5.
49. McCarville MB, Rogers ZR, Sarnaik S, Scott P, Aygun B, Hilliard L, Lee MT, Kalinyak K, Owen W, Garro J, Schultz W, Yovetich N, Ware RE; SWiTCH Investigators: Effects of chronic transfusions on abdominal sonographic abnormalities in children with sickle cell anemia. *J Pediatr*. 2012 Feb;160(2):281-285.
50. DeBaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele G, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Gordon MO, Miller JP, Noetzel MJ, Ichord RN, Casella JF: Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. *Blood*. 2012 Apr 19;119(16):3684-90.
51. Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, Thompson A, Woods GM, Schultz W, Mortier N, Lane P, Mueller B, Yovetich N, Ware RE; for the SWiTCH Study Investigators: Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention. *Am J Hematol*. 2012 February 87(2): 221-223.
52. Aygun B, Wruck LM, Schultz WH, Mueller BU, Brown C, Luchtman-Jones L, Jackson S, Iyer R, Rogers ZR, Sarnaik S, Thompson AA, Gauger C, Helms RW, Ware RE; TCD With Transfusions Changing to Hydroxyurea (TWiTCH) Trial Investigators: Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. *Am J Hematol*. 2012 Apr;87(4):428-30.
53. Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ; Thalassemia Clinical Research Network: Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. *Blood*. 2012 Mar 22; 119(12):2746-53.
54. Miller ST, Kim HY, Weiner D, Wager CG, Gallagher D, Styles L, Dampier CD; Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN): Inpatient management of sickle cell pain: a 'snapshot' of current practice. *Am J Hematol*. 2012 Mar; 87(3):333-6.
55. Ware RE, Helms RW; SWiTCH Investigators: Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). *Blood*. 2012 Apr 26; 119(17):3925-32.
56. Auerswald G, Thompson AA, Recht M, Brown D, Liesner R, Guzman-Becerra N, Dyck-Jones J, Ewenstein B, Abbuehl, B: Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. *Thromb Haemost*. 2012 May 31; 107(6):1072-82.

57. Styles L, Wager CG, Labotka RJ, Smith-Whitley K, Thompson AA, Lane PA, McMahon LE, Miller R, Roseff SD, Iyer RV, Hsu LL, Castro OL, Ataga KI, Onyekwere O, Okam M, Bellevue R, Miller ST; Sickle Cell Disease Clinical Research Network (SCDCRN): Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). Br J Haematol. 2012 Jun; 157(5):627-36.
58. Fung EB, Xu Y, Trachtenberg F, Odame I, Kwiatkowski JL, Neufeld EJ, Thompson AA, Boudreaux J, Quinn CT, Vichinsky EP; Thalassaemia Clinical Research Network: Inadequate Dietary Intake in Patients with Thalassaemia. J Acad Nutr Diet. 2012 Jul; 112(7):980-90.
59. Smith-Whitley K, Thompson AA: Indications and complications of transfusions in sickle cell disease. Pediatr Blood Cancer. 2012 Aug; 59(2):358-64.
60. O'Connor FG, Deuster P, Thompson A: Sickle cell trait: what's a sports medicine clinician to think? Br J Sports Med. 2012 May 19. [Epub ahead of print]
61. O'Connor FG, Bergeron MF, Cantrell J, Connes P, Harmon KG, Ivy E, Kark J, Klossner D, Lisman P, Meyers BK, O'Brien K, Ohene-Frempong K, Thompson AA, Whitehead J, Deuster PA: ACSM and CHAMP Summit on SCT: Mitigating Risks for Warfighters and Athletes. Med Sci Sports Exerc. 2012 Nov;44(11):2045-2056.
62. Andolina JR, Morrison CB, Thompson AA, Chaudhury S, Mack AK, Proytcheva M, Corey SJ: Shwachman-Diamond Syndrome: Diarrhea, no Longer Required? J Pediatr Hematol Oncol. 2012 Aug 29. [Epub ahead of print]
63. Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol. 2012 Nov;159 (4):394-404
64. Haines D, Martin M, Carson S, Oliveros O, Green S, Coates T, Eile J, Schilling L, Dinu B, Mendoza T, Gerstenberger E, Trachtenberg F, Vichinsky E; Thalassaemia Clinical Research Network. Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol. 2013 Mar; 160(5):680-7.. Epub 2012 Dec 30. PMID: 23278768 [PubMed – indexed for MEDLINE]
65. Thompson AA: Sickle cell disease and racism: Real or false barriers? Pediatr Blood Cancer. 2013 Mar; 60(3):349-50.
66. Trachtenberg FL, Mednick L, Kwiatkowski JL, Neufeld EJ, Haines D, Pakbaz Z, Thompson AA, Quinn CT, Grady R, Sobota A, Olivieri N, Horne R, Yamashita R; Thalassaemia Clinical Research Network: Beliefs about chelation among thalassaemia patients. Health Qual Life Outcomes. 2012 Dec 7;10:148.
67. Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ: Genetic and Clinical Determinants Influencing Warfarin Dosing in Children With Heart Disease. Pediatr Cardiol. 2013 Apr;34(4):984-90
68. Gallo, A. M., Wilkie, D. J., Wang, E., Labotka, R J., Molokie, R.E., Stahl, C. Hershberger, P. E., Zhao, Z., Suarez, M. L., Johnson, B., Pullum, C., Angulo, R., & Thompson, A.: Evaluation of the SCKnowIQ Tool and Reproductive CHOICES Intervention among Young Adults with Sickle Cell Disease or Sickle Cell Trait. Clin Nurs Res. 2013 Apr 8. [Epub ahead of print] PMID 23572406

69. Switzer WM, Shankar A, Trimble SR, Thompson AA, Giardina PJ, Cohen AR, Coates TD, Vichinsky E, Neufeld EJ, Boudreaux JM, Heneine W: Human T Cell Lymphotropic Virus Type 1 Infection Among U.S. Thalassemia Patients. *AIDS Res Hum Retroviruses*. 2013 Jul; 29(7):1006-9. PMID: 23409829
70. O'Suoji C, Liem RI, Mack AK, Kingsberry P, Ramsey G, Thompson AA: Alloimmunization in Sickle Cell Anemia in the Era of Extended Red Cell Typing. *Pediatr Blood Cancer*. 2013. Sep; 60(9):1487-91. PMID: 23508932
71. Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, Giardina PJ, Klaassen RJ, Chakraborty P, Geraghty MT, Major-Cook N, Kannengiesser C, Thuret I, Thompson AA, Marques L, Hughes S, Bottomley SS, Fleming MD, Wynn RF: A novel syndrome of congenital sideroblastic anemia, B cell immunodeficiency, periodic fevers and developmental delay (SIFD): *Blood*. 2013 Jul 4;122(1):112-23. PMID: 23553769
72. Morris CR, Kim HY, Wood JC, Porter JB, Klings ES, Trachtenberg FL, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Singer ST, Taher A, Neufeld EJ, Thompson AA, Sachdev V, Larkin S, Suh JH, Kuypers FA, Vichinsky EP: Sildenafil therapy in thalassemia patients with doppler-defined risk for pulmonary hypertension: *Haematologica*. 2013 Sep;98(9):1359-67. PMID: 23585527
73. Lewis KB, Hughes RJ, Epstein MS, Josephson NC, Kempton CL, Kessler CM, Key NS, Howard TE, Kruse-Jarres R, Lusher JM, Walsh CE, Watts RG, Ettinger RA, Pratt KP: PATH (Personalized Alternative Therapies for Haemophilia) Study Investigators: Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance. *PLoS One*. 2013 May 8;8(5): e61120. PMID: 23667433
74. Porter JB, Wood J, Olivieri N, Vichinsky EP, Taher A, Neufeld E, Giardina P, Thompson A, Moore B, Evans P, Kim HY, Macklin EA, Trachtenberg F: Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. *J Cardiovasc Magn Reson*. 2013 May 20;15(1):38. PMID: 23688265
75. Thompson AA, Kim HY, Singer ST, Vichinsky E, Eile J, Yamashita R, Giardina PJ, Olivieri N, Parmar N, Trachtenberg F, Neufeld EJ, Kwiatkowski JL; Thalassemia Clinical Research Network: Pregnancy outcomes in women with thalassemia in North America and the United Kingdom; *Am J Hematol*. 2013 Sep;88(9):771-3. PMID: 23757266
76. Thompson AA: Ideal donors, imperfect results in sickle cell disease. *Blood*. 2013 Aug 8;122(6):858-9. PMID: 23929836
77. Wilkie DJ, Gallo AM, Yao Y, Molokie RE, Stahl C, Hershberger PE, Zhao Z, Suarez ML, Labotka RJ, Johnson B, Angulo R, Angulo V, Carrasco J, Shuey D, Pelligra S, Wang E, Rogers DT, Thompson AA: Reproductive Health Choices for Young Adults With Sickle Cell Disease or Trait: Randomized Controlled Trial Immediate Posttest Effects. *Nurs Res*. 2013 September/October; 62(5):352-361. PMID: 23995469
78. Pandey GS, Yanover C, Miller-Jenkins LM, Garfield S, Cole SA, Curran JE, Moses EK, Rydz N, Simhadri V, Kimchi-Sarfaty C, Lillicrap D, Viel KR, Przytycka TM, Pierce GF, Howard TE, Sauna ZE; the PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators, Lusher J, Chitlur M, Ameri A, Natarajan K, Iyer RV, Thompson AA, Watts RG, Kempton CL, Kessler C, Barrett JC, Martin EJ, Key N, Kruse-Jarres R, Lessinger C, Pratt KP, Josephson N, McRedmond K, Withycombe J, Walsh C, Matthews

- D, Mahlangu J, Krause A, Schwyzer R, Thejpal R, Rapiti N, Goga Y, Coetzee M, Stones D, Mann K, Butenas S, Almasy L, Blangero J, Carless M, Raja R, Reed E: Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. *Nat Med.* 2013 Sep 15. PMID: 24037092.
79. Martin A, Thompson AA: *Thalassemias.* *Pediatr Clin North Am.* 2013 Dec;60(06):1383-91. PMID: 24237977
80. Thompson AA: Sickle cell trait testing and athletic participation: a solution in search of a problem? *Hematology Am Soc Hematol Educ Program.* 2013:632-7. PMID: 24319243
81. Liem RI, O'Suoji C, Kingsberry PS, Pelligra SA, Kwon S, Mason M, Thompson AA: Access to Patient-Centered Medical Homes in Children with Sickle Cell Disease. *Matern Child Health J.* 2014 Jan 5. PMID: 24389958
82. Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, Coates T, Boudreaux J, Neufeld EJ, Kenney K, Grant A, Thompson AA; CDC Thalassemia Investigators. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention. *Transfusion.* 2014 Apr;54(4):972-81; quiz 971. PMID:23889533
83. King AA, Rodeghier MJ, Panepinto JA, Strouse JJ, Casella JF, Quinn CT, Dowling MM, Sarnaik SA, Thompson AA, Woods GM, Minniti CP, Redding-Lallinger RC, Kirby-Allen M, Kirkham FJ, McKinstry R, Noetzel MJ, White DA, Kwiatkowski JK, Howard TH, Kalinyak KA, Inusa B, Rhodes MM, Heiny ME, Fuh B, Fixler JM, Gordon MO, DeBaun MR: *Silent cerebral infarction, income, and grade retention among students with sickle cell anemia.* *Am J Hematol.* 2014 Oct;89(10):E188-92. PMID:25042018
84. Helton KJ, Adams RJ, Kesler KL, Lockhart A, Aygun B, Driscoll C, Heeney MM, Jackson SM, Krishnamurti L, Miller ST, Sarnaik SA, Schultz WH, Ware RE; SWiTC H Investigators: *Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTC H trial.* *Blood.* 2014 Aug 7;124(6):891-8. PMID:24914136
85. Abkowitz JL, O'Connor FG, Deuster PA, Thompson AA: *Sickle cell trait and safe athletic participation: the way forward.* *Curr Sports Med Rep.* 2014 May-Jun;13(3):192-3. PMID:24819012
86. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF: *Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.* *N Engl J Med.* 2014 Aug 21;371(8):699-710. PMID:25140956
87. Roberts DO, Covert B, Rodeghier MJ, Parmar N, DeBaun MR, Thompson AA, Liem RI: *Randomization is not associated with socio-economic and demographic factors in a multi-center clinical trial of children with sickle cell anemia.* *Pediatr Blood Cancer.* 2014 Sep;61(9):1529-35. PMID: 24753128
88. Chakraborty PK, Schmitz-Abe K, Kennedy EK, Mamady H, Naas T, Durie D, Campagna DR, Lau A, Sendamarai AK, Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, Giardina PJ, Klaassen RJ, Kannengiesser C, Thuret I, Thompson AA, Marques L, Hughes S, Bonney DK, Bottomley SS, Wynn RF, Laxer RM, Minniti CP,

- Moppett J, Bordon V, Geraghty M, Joyce PB, Markianos K, Rudner AM, Holcik M, Fleming MD: Mutations in TRNT1, encoding the CCA-adding enzyme, cause congenital sideroblastic anemia with B cell immunodeficiency, periodic fevers and developmental delay (SIFD). *Blood*. 2014 Oct 30;124(18):2867-71 PMID: 25193871
89. Trachtenberg FL, Gerstenberger E, Xu Y, Mednick L, Sobota A, Ware H, Thompson AA, Neufeld EJ, Yamashita R: Relationship among chelator adherence, change in chelators, and quality of life in Thalassemia. *Qual Life Res*. 2014 Oct;23(8):2277-88. PMID:24682717
 90. Alvarado AM, Ward KM, Muntz DS, Thompson AA, Rodeghier M, Fernhall B, Liem RI: Heart rate recovery is impaired after maximal exercise testing in children with sickle cell anemia. *J Pediatr*. 2015 Feb;166(2):389-393 PMID 25477159
 91. Aygun B, Mortier NA, Kesler K, Lockhart A, Schultz WH, Cohen AR, Alvarez O, Rogers ZR, Kwiatkowski JL, Miller ST, Sylvestre P, Iyer R, Lane PA, Ware RE; Stroke With Transfusions Changing to Hydroxyurea (SWITCH) Trial Investigators. Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. *Br J Haematol*. 2015 Apr;169(2):262-6. PMID: 25612463
 92. Liem RI, Reddy M, Pelligra SA, Savant AP, Fernhall B, Rodeghier M, Thompson AA: Reduced fitness and abnormal cardiopulmonary responses to maximal exercise testing in children and young adults with sickle cell anemia. *Physiol Rep*. 2015 Apr;3(4). pii: e12338. PMID: 25847915
 93. Listernick R, Benya E, Trainor J, Kabre R, Lautz T, Sharathkumar A, Liem R, Bhat R, Rozenfeld R, Thompson A, Sharathkumar A: A 15-year-old obese girl with abdominal pain. *Pediatr Ann*. 2015 Apr;44(4):126-9. PMID:25875976
 94. Morris CR, Kim HY, Klings ES, Wood J, Porter JB, Trachtenberg F, Sweeters N, Olivieri NF, Kwiatkowski JL, Virzi L, Hassell K, Taher A, Neufeld EJ, Thompson AA, Larkin S, Suh JH, Vichinsky EP, Kuypers FA; Thalassemia Clinical Research Network. Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. *Br J Haematol*. 2015 Jun;169 (6):887-98..PMID:25907665
 95. Hershberger PE, Gallo AM, Molokie R, Thompson AA, Suarez ML, Yao Y, Wilkie DJ: Perception of young adults with sickle cell disease or sickle cell trait about participation in the CHOICES randomized controlled trial. *J Adv Nurs*. 2015 Jun 15. PMID: 26073718
 96. Tubman VN, Fung EB, Vogiatzi M, Thompson AA, Rogers ZR, Neufeld EJ, Kwiatkowski JL; Thalassemia Clinical Research Network: Guidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort. *J Pediatr Hematol Oncol*. 2015 Apr;37(3):e162-9. PMID:26201037
 97. Gallo AM, Wilkie DJ, Yao Y, Molokie RE, Stahl C, Hershberger PE, Zhao Z, Suarez ML, Johnson B, Angulo R, Carrasco J, Angulo V, Thompson AA: Reproductive Health CHOICES for Young Adults with Sickle Cell Disease or Trait: Randomized Controlled Trial Outcomes over Two Years. *J Genet Couns*. 2015 Aug 28. 25(2), 325-336 PMID:26310871
 98. Liem RI, Onyejekwe K, Olszewski M, Nchekwube C, Zaldivar FP, Radom-Aizik S, Rodeghier MJ, Thompson AA: The acute phase inflammatory response to maximal exercise testing in children and young adults with sickle cell anaemia. *Br J Haematol*. 2015 Dec;171 (5):854-61 PMID: 26456230

99. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ: Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. *Lancet*. 2016 Feb 13;387(10019):661-70. PMID: 26670617
100. Wood JC, Cohen AR, Pressel SL, Aygun B, Imran H, Luchtman-Jones L, Thompson AA, Fuh B, Schultz WH, Davis BR, Ware RE; TWiTCH Investigators: Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial. *Br J Haematol*. 2016 Jan;172 (1):122-30 PMID: 26523836
101. Clayton-Jones D, Haglund K, Belknap RA, Schaefer J, Thompson AA: Spirituality and Religiosity in Adolescents Living With Sickle Cell Disease. *West J Nurs Res*. 2016 Jan 19. pii: 0193945915625065. PMID: 26792855
102. Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE: Effects of hydroxyurea treatment for patients with hemoglobin SC disease. *Am J Hematol*. 2016 Feb;91(2):238-42. PMID: 26615793
103. Badawy SM, Thompson AA, Liem RI: Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease. *Pediatr Blood Cancer*. 2016 Feb 4. PMID: 26844685
104. Shenoy S, Thompson AA: Unrelated donor stem cell transplantation for transfusion-dependent thalassemia. *Ann N Y Acad Sci*. 2016 Mar;1368(1):122-6. doi: 10.1111/nyas.13019. PMID: 26999376
105. Badawy SM, Thompson AA, Sand M: In-flight emergencies: Medical kits are not good enough for kids. *J Paediatr Child Health*. 2016 Apr;52(4):363-5. PMID: 27145496
106. Hershberger PE, Gallo AM, Molokie R, Thompson AA, Suarez ML, Yao Y, Dallas CM, Wilkie DJ: Toward understanding family-related characteristics of young adults with sickle-cell disease or sickle-cell trait in the USA: *J Clin Nurs*. 2016 Jun;25(11-12):1587-97. doi: 10.1111/jocn.13144. PMID: 26970444
107. Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF; Pediatric ITP Consortium of North America (ICON). Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. *Pediatr Blood Cancer*. 2016 Aug; 63(8):1407-13. doi: 10.1002/pbc.26003 PMID: 27135461
108. Hinton CF, Homer CJ, Thompson AA, Williams A, Hassell KL, Feuchtbaum L, Berry SA, Comeau AM, Therrell BL, Brower A, Harris KB, Brown C, Monaco J, Ostrander RJ, Zuckerman AE, Kaye C, Dougherty D, Greene C, Green NS; Follow-up and Treatment Sub-committee of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC): A framework for assessing outcomes from newborn screening: on the road to measuring its promise. *Mol Genet Metab*. 2016 Aug;118(4):221-9. doi:

- 10.1016/j.ymgme.2016.05.017. Epub 2016 May 31. PMID: 27268406
109. Cronin RM, Hankins JS, Adams-Graves P, Thompson AA, Kalinyak K, Byrd J, McClain B, Kassim A, DeBaun M, Treadwell M: Barriers and Facilitators to Research Participation Among Adults, and Parents of Children with Sickle Cell Disease: A Trans-regional Survey. Am J Hematol. 2016 Jul 16. doi: 10.1002/ajh.24483. PMID: 27421796
 110. Badawy SM, Liem RI, Rigsby CK, Labotka RJ, DeFreitas RA, Thompson AA. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease. Br J Haematol. 2016 Aug 10. doi: 10.1111/bjh.14277. PMID: 27507431
 111. Thompson AA: New developments in the management of sickle cell disease. Blood Adv. 2016 Nov 22;1(1):3. doi: 10.1182/bloodadvances.2016000539. eCollection 2016 Nov 29. PMID 29296688
 112. Liem RI, Chan C, Vu TT, Fornage M, Thompson AA, Liu K, Carnethon MR: Longitudinal association among sickle cell trait, fitness, and cardiovascular disease risk factors in African Americans in CARDIA. Blood. 2017 Feb 9;129(6):723-728. doi: 10.1182/blood-2016-07-727719. Epub 2016 Nov 16 PMID: 27856464
 113. Mack AK, Thompson AA: Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease. J Pediatr Health Care. 2017 Mar - Apr;31 (2):145-154. doi: 10.1016/j.pedhc.2016.06.005. Epub 2016 Jul 14. PMID: 27423528
 114. Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI: Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2017 Jun;64(6) doi: 10.1002/pbc.26369. PMID: 27896936
 115. Thompson AA: Making a case for more sickle cell initiatives in Africa. Blood. 2017 Jan 12;129 (2):136-137. doi: 10.1182/blood-2016-11-751933 PMID:28082288
 116. Badawy SM, Thompson AA, Penedo FJ, Lai JS, Rychlik K, Liem RI: Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. 2017 Jun;98 (6):608-614. doi: 10.1111/ejh.12878. PMID:28306171
 117. Liem RI, Akinosun M, Muntz DS, Thompson AA.: Feasibility and safety of home exercise training in children with sickle cell anemia. Pediatr Blood Cancer. 2017 Dec;64 (12). doi: 10.1002/pbc.26671. PMID: 28598539
 118. Omwanghe OA, Muntz DS, Kwon S, Montgomery S, Kemiki O, Hsu LL, Thompson AA, Liem RI.: Self-Reported Physical Activity and Exercise Patterns in Children With Sickle Cell Disease. Pediatr Exerc Sci. 2017 Aug;29 (3):388-395. doi: 10.1123/pes.2016-0276. PMID: 28530510
 119. Badawy SM, Thompson AA, Penedo FJ, Lai JS, Rychlik K, Liem RI: Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. 2017 Mar 17. doi: 10.1111/ejh.12878. PMID:28306171
 120. Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI: Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health Qual Life Outcomes. 2017 Jul 5;15(1):136. doi: 10.1186/s12955-017-0713-x. PMID 28679417
 121. Chaudhury S, Ayas M, Rosen C, Ma M, Viqaruddin M, Parikh S, Kharbanda S, Chiang KY, Haight A, Bhatia M, Guilcher G, Thompson A, Shenoy S: A Multicenter

- Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for β -Thalassemia. *Biol Blood Marrow Transplant.* 2017 Oct;23(10):1695-1700. doi: 10.1016/j.bbmt.2017.06.004.. PMID: 28627425
122. Badawy SM, Thompson AA, Kuhns LM: Medication Adherence and Technology-Based Interventions for Adolescents With Chronic Health Conditions: A Few Key Considerations. *JMIR Mhealth Uhealth.* 2017 Dec 22;5(12):e202. doi: 10.2196/mhealth.8310. PMID 29273573
123. Badawy SM, Thompson AA, Liem RI: Beliefs about hydroxyurea in youth with sickle cell disease *Hematol Oncol Stem Cell Ther.* 2018 Jan 31. pii: S1658-3876(18)30002-5. doi: 10.1016/j.hemonc.2018.01.001. PMID 29397333
124. Shenoy S, Walters MC, Ngwube A, Soni S, Jacobsohn D, Chaudhury S, Grimley M, Chan K, Haight A, Kasow KA, Parikh S, Andreansky M, Connelly J, Delgado D, Godder K, Hale G, Nieder M, Pulsipher MA, Trachtenberg F, Neufeld E, Kwiatkowski JL, Thompson AA: Unrelated Donor Transplantation in Children with Thalassemia Using Reduced Intensity Conditioning - the UTRH Trial. *Biol Blood Marrow Transplant.* 2018 Jan 25. pii: S1083-8791(18)30039-9. doi: 10.1016/j.bbmt.2018.01.023. PMID 29374585
125. Cronin RM, Hankins JS, Byrd J, Pernell BM, Kassim A, Adams-Graves P, Thompson AA, Kalinyak K, DeBaun MR, Treadwell M. Modifying factors of the health belief model associated with missed clinic appointments among individuals with sickle cell disease. *Hematology.* 2018 Mar 29;1-9. doi: 10.1080/10245332.2018.1457200. [Epub ahead of print] PMID:29595096
126. Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM, Fermo E, Lezon-Geyda K, Morton DH, Neufeld EJ, Chonat S, Kollmar N, Knoll CM, Kuo K, Kwiatkowski JL, Pospíšilová D, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauser S, Breakey VR, Kunz J, Sheth S, Rose MJ, Bradeen HA, Neu N, Guo D, Al-Sayegh H, London WB, Gallagher PG, Zanella A, Barcellini W. The clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. *Blood.* 2018 Mar 16. pii: blood-2017-10-810796. doi: 10.1182/blood-2017-10-810796. [Epub ahead of print] PMID:29549173
127. Grace RF, Despotovic JM, Bennett CM, Bussel JB, Neier M, Neunert C, Crary SE, Pastore YD, Klaassen RJ, Rothman JA, Hege K, Breakey VR, Rose MJ, Shimano KA, Buchanan GR, Geddis A, Haley KM, Lorenzana A, Thompson A, Jeng M, Neufeld EJ, Brown T, Forbes PW, Lambert MP. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. *Am J Hematol.* 2018 Apr 16. doi: 10.1002/ajh.25110. [Epub ahead of print] PMID:29659042
128. Vichinsky E, Cohen A, Thompson AA, Giardina PJ, Lal A, Paley C, Cheng WY, McCormick N, Sasane M, Qiu Y, Kwiatkowski JL. Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States. *Pediatr Blood Cancer.* 2018 Apr 10:e27067. doi: 10.1002/pbc.27067. [Epub ahead of print] PMID:29637688
129. Thompson AA, Walters MC, Kwiatkowski J, Rasko JEJ, Ribeil JA, Hongeng S, Magrin E, Schiller GJ, Payen E, Semeraro M, Moshous D, Lefrere F, Puy H, Bourget P, Magnani A, Caccavelli L, Diana JS, Suarez F, Monpoux F, Brousse V, Poirot C, Brouzes C, Meritet JF, Pondarré C, Beuzard Y, Chrétien S, Lefebvre T, Teachey DT, Anurathapan U, Ho PJ, von Kalle C, Kletzel M, Vichinsky E, Soni S, Veres G, Negre O, Ross RW,

- Davidson D, Petrusich A, Sandler L, Asmal M, Hermine O, De Montalembert M, Hacein-Bey-Abina S, Blanche S, Leboulch P, Cavazzana M. Gene Therapy in Patients with Transfusion-Dependent β -Thalassemia. *N Engl J Med*. 2018 Apr 19;378(16):1479-1493. doi: 10.1056/NEJMoa1705342. PMID:29669226
130. Badawy SM, Morrone K, Thompson A, Palermo TM. Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia. *Cochrane Database Syst Rev*. 2017 Dec;2017(12). pii: CD012900. Epub 2017 Dec 14. PMID:29861660
 131. Badawy SM, Cronin RM, Hankins J, Crosby L, DeBaun M, Thompson AA, Shah N. Patient-centered ehealth interventions for children, adolescents and adults with sickle cell disease: systematic review. *J Med Internet Res*. 2018 Jul 19;20(7):e10940. doi: 10.2196/10940. Review. PMID:30026178
 132. Hammond J, Thompson AA, Fogel MA, Hammond K, Kokroko J, Kwiatkowski JL. Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden. *J Pediatr Hematol Oncol*. 2019 Jan;41(1):e47-e50. PMID:30080754
 133. Badawy SM, Barrera L, Cai S, Thompson AA. Association between Participants' Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease. *Biomed Res Int*. 2018 Jul 18;2018:8296139. doi: 10.1155/2018/8296139. eCollection 2018. PMID:30105252
 134. van Beers EJ, van Straaten S, Morton DH, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA, Sharma M, Neufeld EJ, Sheth S, Despotovic JM, Kollmar N, Pospíšilová D, Knoll CM, Kuo K, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauer S, Breakey VR, Verhovsek M, Kunz J, McNaull MA, Rose MJ, Bradeen HA, Addonizio K, Li A, Al-Sayegh H, London WB, Grace RF. Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. *Haematologica*. 2019 Feb;104(2):e51-e53. doi: 10.3324/haematol.2018.196295. Epub 2018 Sep 13. PMID:30213831
 135. Cronin RM, Hankins JS, Byrd J, Pernell BM, Kassim A, Adams-Graves P, Thompson A, Kalinyak K, DeBaun M, Treadwell M. Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study. *Hematology*. 2019 Dec;24(1):189-198. doi: 10.1080/16078454.2018.1549801. PMID:30479187
 136. Badawy SM, Thompson AA, Holl JL, Penedo FJ, Liem RI. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease *Pediatr Hematol Oncol*. 2018 Aug - Sep;35(5-6):297-308. doi: 10.1080/08880018.2018.1505988. Epub 2019 Jan 12. PMID:30636474
 137. Rogers ZR, Nakano TA, Olson TS, Bertuch AA, Wang W, Gillio A, Coates TD, Chawla A, Castillo P, Kurre P, Gamper C, Bennett CM, Joshi S, Geddis AE, Boklan J, Nalepa G, Rothman JA, Huang JN, Kupfer GM, Cada M, Glader B, Walkovich KJ, Thompson AA, Hanna R, Vlachos A, Malsch M, Weller EA, Williams DA, Shimamura A: Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. *Haematologica*. 2019 Apr 4. pii: haematol.2018.206540 PMID: 30948484

138. Thompson AA: A Targeted Agent for Sickle Cell Disease - Changing the Protein but Not the Gene. *N Engl J Med.* 2019 Aug 8;381(6):579-580. doi: 10.1056/NEJMe1906771. Epub 2019 Jun 14 PMID 31199089
139. Badawy SM, Morrone K, Thompson A, Palermo TM. Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia. *Cochrane Database Syst Rev.* 2019 Jun 28;6:CD012900. doi: 10.1002/14651858.CD012900.pub2 PMID 31250923
140. Kaur M, Brown M, Love TW, Thompson A, Treadwell M, Smith-Whitley K: Understanding sickle cell disease: impact of surveillance and gaps in knowledge. *Blood Adv.* 2020 Feb 11;4(3):496-498. doi: 10.1182/bloodadvances.2019001000. No abstract available. PMID: 32027743
141. Majumdar S, Bean CJ, De Staercke C, Bost J, Nickel R, Coates T, Campbell A, Thompson A: Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project. *Transfus Med.* 2020 Mar 4. doi 10.1111/tme. 12671 PMID:32131139
142. Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A; BELIEVE Investigators: A phase 3 trial of luspatercept in patients with transfusion-dependent beta thalassemia. *N Engl J Med.* 2020 Mar 26;382(13):1219-1231. doi: 10.1056/NEJMoa1910182. PMID: 32212518
143. Barriteau CM, Murdoch A, Gallagher SJ, Thompson AA: A patient-centered medical home model for comprehensive sickle cell care in infants and young children. *Am J Hematol.* 2020 May 13. doi: 10.1002/ajh.25867. PMID: 32401372
144. Hsieh MM, Bonner M, Pierciey FJ, Uchida N, Rottman J, Demopoulos L, Schmidt M, Kanter J, Walters MC, Thompson AA, Asmal M, Tisdale JF: Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. *Blood Adv.* 2020 May 12;4(9):2058-2063. doi: 10.1182/bloodadvances.2019001330 PMID:32396618
145. Tisdale JF, Pierciey FJ Jr, Bonner M, Thompson AA, Krishnamurti L, Mapara MY, Kwiatkowski JL, Shestopalov I, Ribeil JA, Huang W, Asmal M, Kanter J, Walters MC: Safety and Feasibility of Hematopoietic Progenitor Stem Cell Collection by Mobilization with Plerixafor Followed by Apheresis vs Bone Marrow Harvest in Patients with Sickle Cell Disease in the Multi-center HGB-206 Trial. *Am J Hematol.* 2020 May 13. doi: 10.1002/ajh.25867 PMID: 32401372
146. Al-Samkari H, Addonizio K, Glader B, Morton DH, Chonat S, Thompson AA, Kuo KHM, Ravindranath Y, Wang H, Rothman JA, Kwiatkowski JL, Kung C, Kosinski PA, Al-Sayegh H, London WB, Grace RF: The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. *Br J Haematol.* 2020 May 28. PMID: 32463523
147. Harmon KG, Pottinger PS, Baggish AL, Drezner JA, Luks AM, Thompson AA, Swaminathan S: Comorbid medical conditions in young athletes: considerations for preparticipation guidance during COVID-19 pandemic. *Sports Health.* 2020

Sep/Oct;12(5):456-458. doi: 10.1177/1941738120939079. Epub 2020 Jun 24.
PMID: 32579436

148. Cronin RM, Yang M, Hankins JS, Byrd J, Pernel BM, Kassim A, Adams-Graves P, Thompson AA, Kalinyak K, DeBaun M, Treadwell M: Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease. *Hematology*. 2020 Dec;25(1):229-240. doi: 10.1080/16078454.2020.1780737. PMID: 32552526
149. O'Connor FG, Franzos MA, Nye NS, Nelson DA, Shell D, Voss JD, Anderson SA, Coleman NJ, Thompson AA, Harmon KG, Deuster PA: Summit on Exercise Collapse Associated with Sickle Cell Trait: Finding the "Way Ahead" *Curr Sports Med Rep*. 2021 Jan 1;20(1):47-56. PMID: 33395130
150. Badawy SM, Beg U, Liem RI, Chaudhury S, Thompson AA: A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy *Blood Adv*. 2021 Jan 26;5(2):570-583. PMID: 33496753
151. Casella JF, Barton BA, Kanter J, Black LV, Majumdar S, Inati A, Wali Y, Drachtman RA, Abboud MR, Kilinc Y, Fuh BR, Al-Khabori MK, Takemoto CM, Salman E, Sarnaik SA, Shah N, Morris CR, Keates-Baleeiro J, Raj A, Alvarez OA, Hsu LL, Thompson AA, Sisler IY, Pace BS, Noronha SA, Lasky JL 3rd, de Julian EC, Godder K, Thornburg CD, Kamberos NL, Nuss R, Marsh AM, Owen WC, Schaefer A, Tebbi CK, Chantrain CF, Cohen DE, Karakas Z, Piccone CM, George A, Fixler JM, Singleton TC, Moulton T, Quinn CT, de Castro Lobo CL, Almomen AM, Goyal-Khemka M, Maes P, Emanuele M, Gorney RT, Padgett CS, Parsley E, Kronsberg SS, Kato GJ, Gladwin MT: Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial *JAMA*. 2021 Apr 20;325(15):1513-1523. doi: 10.1001/jama.2021.3414. PMID: 33877274
152. Hood AM, Strong H, Nwankwo C, Johnson Y, Peugh J, Mara CA, Shook LM, Brinkman WB, Real FJ, Klein MD, Hackworth R, Badawy SM, Thompson AA, Raphael JL, Yates AM, Smith-Whitley K, King AA, Calhoun C, Creary SE, Piccone CM, Hildenbrand AK, Reader SK, Neumayr L, Meier ER, Sobota AE, Rana S, Britto M, Saving KL, Treadwell M, Quinn CT, Ware RE, Crosby LE: Engaging Caregivers and Providers of Childrens with Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. *JMIR Res Protoc*. 2021 May 21;10(5):e27650. doi: 10.2196/27650. PMID: 34018965
153. Ballas SK, Kuypers FA, Gordeuk VR, Hankins JS, Thompson AA, Vichinsky E: Time to rethink haemoglobin threshold guidelines in sickle cell diseases. *Br J Haematol* 2021 Jun 15 doi:10.1111/bjh. 17558. PMID 34131897
154. Badawy SM, Payne AB, Hulihan MM, Coates TD, Majumdar S, Smith D, Thompson AA: Concordance with comprehensive iron assessment, hepatitis A vaccination and Hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project. *Br J Haematol*. 2021 Aug 24. doi: 10.1111/bjh.17798. PMID: 34431082
155. MacKenzie TC, Amid A, Angastiniotis M, Butler C, Gilbert S, Gonzalez J, Keller RL, Kharbanda S, Kirby-Allen MA, Koenig BA, Kyono W, Lal A, Lianoglou BR, Norton ME, Ogasawara KK, Panchalee T, Rosner M, Schwab ME, Thompson AA, Waye JS, Vichinsky E.: Consensus statement for the perinatal management of patients with alpha

- thalassemia major. *Blood Adv.* 2021 Nov 8: 2021005916. doi: 10.1182/bloodadvances.2021005916. PMID: 3474939
156. Chapin J, Cohen AR, Neufeld EJ, Vichinsky E, Giardina PJ, Boudreaux J, Le BC, Kenney K, Trimble S, Thompson AA.: An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres. *Br J Haematol.* 2021 Nov 14. doi: 10.1111/bjh.17920.PMID: 34775608
157. Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, Sauer MG, Thuret I, Lal A, Algeri M, Schneiderman J, Olson TS, Carpenter B, Amrolia PJ, Anurathapan U, Schambach A, Chabannon C, Schmidt M, Labik I, Elliot H, Guo R, Asmal M, Colvin RA, Walters MC: Betibeglogene Autotemcel Gene Therapy for Non- β^0/β^0 Genotype β -Thalassemia. *N Engl J Med.* 2021 Dec 11. doi: 10.1056/NEJMoa2113206. PMID: 34891223
158. Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, Aygun B, Kasow KA, Pierciey FJ Jr, Bonner M, Miller A, Zhang X, Lynch J, Kim D, Ribeil JA, Asmal M, Goyal S, Thompson AA, Tisdale JF: Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. *N Engl J Med.* 2021 Dec 12. doi: 10.1056/NEJMoa2117175. PMID: 34898139
159. Wood WA, Marks P, Plovnick RM, Hewitt K, Neuberg DS, Walters S, Dolan BK, Tucker EA, Abrams CS, Thompson AA, Anderson KC, Kluetz P, Farrell A, Rivera D, Gertzog M, Pappas G: ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology. *Blood Adv.* 2021 Dec 14;5(23):5429-5438. doi: 10.1182/bloodadvances.2021005902. PMID: 34673922
160. Aygun B, Bello A, Thompson AA, Davis L, Sun Y, Luo HY, Cui S, Chui DHK: Clinical phenotype of three children with sickle cell disease caused by HbS/Sicilian ($\delta\beta$)⁰ thalassemia. *Am J Hematol.* 2022 Jan 19. doi: 10.1002/ajh.26470. PMID: 35045200
161. Pollard JA, Furutani E, Liu S, Esrick E, Cohen LE, Bledsoe J, Liu CW, Lu K, de Haro MJR, Surrallés J, Malsch M, Kuniholm A, Galvin A, Armant M, Kim AS, Ballotti K, Moreau L, Zhou Y, Babushok D, Boulad F, Carroll C, Hartung H, Hont A, Nakano T, Olson T, Sze SG, Thompson AA, Wlodarski MW, Gu X, Libermann TA, D'Andrea A, Grompe M, Weller E, Shimamura A.: Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. *Blood Adv.* 2022 Jun 28;6(12):3803-3811. doi: 10.1182/bloodadvances.2021006490.PMID: 35500223
162. O'Connor FG, Franzos MA, Nye NS, Nelson DA, Shell D, Voss JD, Anderson SA, Coleman NJ, Thompson AA, Harmon KG, Deuster PA: Response to Letter to the Editor. *Curr Sports Med Rep.* 2022 May 1;21(5):164-165. doi: 10.1249/JSR.0000000000000958. PMID: 35522442
163. Taher AT, Cappellini MD, Kattamis A, Voskaridou E, Perrotta S, Piga AG, Filosa A, Porter JB, Coates TD, Forni GL, Thompson AA, Tartaglione I, Musallam KM, Backstrom JT, Esposito O, Giuseppi AC, Kuo WL, Miteva D, Lord-Bessen J, Yucel A, Zinger T, Shetty JK, Viprakasit V; BEYOND Investigators. Luspatercept for the treatment of anaemia in non-transfusion-dependent β -thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial. *Lancet Haematol.* 2022 Oct;9(10):e733-e744. PMID: 36007538
164. Kanter J, Thompson AA, Pierciey FJ Jr, Hsieh M, Uchida N, Leboulch P, Schmidt M, Bonner M, Guo R, Miller A, Ribeil JA, Davidson D, Asmal M, Walters MC, Tisdale JF.

- Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. *Am J Hematol.* 2022 Sep 25. PMID: 36161320
165. DeBaun M, Heeney M, Jackson T, Longo D, Love M, Love T, Okwo P, Thompson A, Trimmell C, Woolford T. Sickle Cell Disease and Gene Therapy - Patient and Physician Perspectives. *N Engl J Med.* 2022 Sep 29;387(13):e28. Doi:10.1056/NEJMp2212269. PMID: 36170507
 166. Badawy SM, DiMartino L, Brambilla D, Klesges L, Baumann A, Burns E, DeMartino T, Jacobs S, Khan H, Nwosu C, Shah N, Hankins JS; Sickle Cell Disease Implementation Consortium. Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study. *JMIR Form Res.* 2022 Oct 14;6(10):e41415. doi: 10.2196/41415. PMID: 36240004
 167. Green NS, Zapfel A, Nnodu OE, Franklin P, Tubman VN, Chirande LF, Kiyaga C, Chunda-Liyoka CM, Awuonda B, Ohene-Frempong K, Inusa BP, Ware RE, Odame I, Ambrose EE, Dogara LG, Oron AP, Willett C, Thompson AA, Berliner N, Coetzer TL, Novelli EM. The consortium on newborn screening in Africa for sickle cell disease: study rationale and methodology. *Blood Adv.* 2022 Oct 20:bloodadvances.2022007698. doi: 10.1182/bloodadvances.2022007698. PMID: 36264096.
 168. MacKenzie TC, Schwab ME, Lianoglou BR, Gano D, Gonzalez J, Arvon RL, Baschat AA, Bianchi DW, Bitanga M, Bourguignon A, Brown RN, Chen B, Chien M, Davis-Nelson S, de Laat MWM, Ekwattanakit S, Gollin Y, Hirata G, Jelin A, Jolley J, Meyer P, Miller J, Norton ME, Ogasawara KK, Panchalee T, Schindewolf E, Shaw SW, Stumbaugh TL, Thompson AA, Towner D, Tsai PS, Viprakasit V, Volanakis E, Vichinsky E, Allen IE, Zhang L. The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry. *Blood Adv.* 2022 Oct 28:bloodadvances.2022007823. doi: 10.1182/bloodadvances.2022007823. Online ahead of print. PMID: 36306387
 169. Eapen M, Brazauskas R, Williams DA, Walters MC, St Martin A, Jacobs BL, Antin JH, Bona K, Chaudhury S, Coleman-Cowger VH, DiFronzo NL, Esrick EB, Field JJ, Fitzhugh CD, Kanter J, Kapoor N, Kohn DB, Krishnamurti L, London WB, Pulsipher MA, Talib S, Thompson AA, Waller EK, Wun T, Horowitz MM. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. *J Clin Oncol.* 2023 Jan 9;JCO2201203. doi: 10.1200/JCO.22.01203. Online ahead of print. PMID: 36623245

Invited Presentations (Selected, past 5 years)

- 3/2018: “Thalassemia,” Highlights of ASH in Asia, Bali, Indonesia
- 4/2018: “Gene Therapy in Hemoglobinopathies,” British Society of Hematology Annual Meeting, Liverpool, UK
- 4/2018: “Sickle Cell Disease,” Highlights of ASH in Latin America, Rio de Janeiro, Brazil

- 7/2018: “Essential Skills for Emerging Leaders,” ASH Clinical Research Training Institute, La Jolla, CA
- 9/2018: “Rising Tides: Advances in Thalassemia,” William C. Moloney Lecture, Brigham and Women’s Hospital, Harvard Medical School, Boston MA
- 10/2018: “Update on Gene Addition Approaches in Sickle Cell Disease,” Sickle Cell in Focus Conference, NHLBI, Bethesda, MD
- “Advances in Gene Therapy for Blood Disorders,” Japanese Society of Hematology Annual Scientific Congress, Osaka, Japan
- 11/2018: “Advances in Curative Therapies for Hemoglobinopathies,” Paul M. Aggeler Memorial Lecture, UCSF/ZSFGH, San Francisco, CA
- 2/2019: “Cure within Reach: Genomic Therapies for Sickle Cell and Thalassemia,” Yale Cancer Center Hematology Research Series, New Haven, CT
- 3/2019: “Gene Addition Approach for Sickle Cell and Thalassemia,” European School of Haematology, Budapest, Hungary
- 4/2019: “Genomic Therapies for Sickle Cell Disease and Thalassemia,” ASH/BSH Joint Symposium, BSH Annual meeting, Glasgow, Scotland, UK
- “Thrombotic Complications in Hereditary Hemolytic Anemias,” Agrupacion Mexicana para el Estudio de la Hematologia (AMEH), annual meeting Chihuahua, Mexico
- “Advances in Hereditary Hemolytic Anemias,” Agrupacion Mexicana para el Estudio de la Hematologia (AMEH), annual meeting Chihuahua, Mexico
- “Endpoints for Curative Therapies: How will be measure success?” 4th Annual Alpha Stem Cell Clinic Conference, California Institute for Regenerative Medicine, San Francisco, CA
- 5/2019: “Cure within Reach: Genomic Therapies for Sickle Cell and Thalassemia, Gwynne Hazen Cherry Family/Stephen A. Feig, M.D. Endowed Lecturer, UCLA, Los Angeles, CA
- 6/2019: “Cure within Reach: Genomic Therapies for Sickle Cell and Thalassemia,” Medicine Grand Rounds, University of Illinois, Chicago IL
- 7/2019: “Sickle Cell Disease in the 21st Century: Emerging Landscape in Diagnosis, Treatment and Health Outcomes,” Roland B. Scott Symposium, National Medical Association Annual Scientific Conference, Honolulu Hawaii

- 9/2019: “How will genomic therapies change the fate of patients with hemoglobin disorders?” Stem Cell Transplantation in Childhood Symposium, Rome, Italy
- 10/2019: “Cure within Reach: Genomic Therapies for Sickle Cell and Thalassemia,” Medicine Grand Rounds, Northwestern University, Chicago IL
- “Genomic Therapies for Sickle Cell and Thalassemia,” Alexander S. Weiner Memorial Lecture, New York Blood Center, New York City, NY
- “Genomic Approaches in Thalassemia,” Annual Sickle Cell and Thalassemia conference, London, England, UK
- Grand Rounds, NHS Guys’ and St Thomas’ Hospitals, London, England, UK
- 01/2020: Advances in Sickle Cell Disease, Grand Rounds, Morehouse School of Medicine
- 02/2020: “Sickle cell disease and thalassemia,” Highlights of ASH in Mediterranean, Athens, Greece
- 10/2020: “Gamechangers: Progress in Sickle Cell Disease,” Grand Rounds, Levine Cancer Institute, Charlotte, North Carolina
- Alpha Omega Alpha Grand Rounds, Tulane University School of Medicine, New Orleans, LA
- 11/2020: Keynote Speaker, Foundation for Blood Disorders in Women and Girl, Annual Scientific Conference
- 12/2020: “Applying for your first job,” Trainee Workshop, Hemostasis and Thrombosis Research Society
- “Leadership” ASH-a-Palooza Trainee Day, ASH Annual Meeting
- 01/2021 “Hematopoietic Stem Cell Transplantation for Alpha Thalassemia Major,” UCSF Alpha Thalassemia Major conference
- 02/2021 “Gene therapy for hemoglobinopathies,” American Society of Transplantation and Cellular Therapies Annual Meeting
- 03/2021 Panelist, “Sickle Cell Disease and Racial Health Disparities in Underfunded Disease,” American Institute for Medical and Biological Engineering (AIMBE)
- “Sickle cell disease and thalassemia,” Highlights of ASH in Mediterranean
- 04/2021 “Genomic Therapies for Hemoglobinopathies: Ready for Prime Time?” Keynote Speaker, Texas Children’s Cancer and Hematology Centers Research symposium

Part 2

Luminary Speaker, Plenary Session, American Society of Pediatric Hematology Oncology Annual Meeting

06/2021 “Bone marrow transplantation and other curative approaches in thalassemia,” Public Health Webinar Series on Blood Disorders, Center for Disease Control and Prevention

“BMT vs Gene Therapy vs No Cell Therapy: Accessibility, Cost and Outcomes” Invited Plenary Speaker, International Society for Cell and Gene Therapy Annual Meeting

07/2021 “Gene Therapy for Sickle Cell Disease” Sickle Treatment and Outcome Research in the Midwest (STORM) Tele-ECHO Seminar Series

09/2021 Keynote Speaker, “Keeping Our Eyes on the Prize: Improving Health Outcomes in Sickle Cell Disease,” Sickle Cell Disease Foundation of Georgia Annual Conference

11/2021 Grand Rounds, “Are We There Yet: Gene Therapy for Hemoglobinopathies,” Yale University School of Medicine, Department of Pediatrics

Invited Speaker, “Updates on Sickle Cell and Thalassemia,” Turkish Society of Hematology-American Society of Hematology Joint Session, Turkish Hematology National Congress

03/2022 Grand Rounds, “Moving into the Era of Novel Therapies for Hemoglobinopathies: Are we there yet?” Children’s Hospital of Philadelphia, Philadelphia, PA

04/2022 “On Cusp Evaluating the Intricacies of Hematopoietic Stem Cell Transplant and Gene Therapy for Hemoglobinopathies” American Society of Transplantation and Cellular Therapy

05/2022 “Genomic Therapies for Hemoglobinopathies: Ready for Prime Time?” C.J. Watson Memorial Lecture, University of Minnesota, Minneapolis MN

06/2022 Plenary Keynote, “Gene Therapy and Bone Marrow Transplantation in Hemoglobinopathies,” European Hematology Association Annual Meeting, Vienna, Austria

Plenary Keynote, “Progress in Management of Sickle Cell Disease – since 3rd Global Congress in 2017,” Global Sickle Cell Disease Network 4th Global Congress, Paris, France

07/2022 “Curative Therapies: Where Are We Now?” Cooley’s Anemia Foundation Annual Patient and Family Conference, Chicago, IL

- 09/2022 "Update on Curative Therapy for Thalassemia", Beta-Thalassemia GeneReviews, Virtual
- "Sickle Cell Disease: From Past to Present to the Future", Congressional Black Caucus Foundation Annual Legislative Conference, Washington, DC
- 10/2022 "Is Gene Therapy a Cure for Thalassemia?", New York Academy of Sciences, New York, New York
- "Reducing the Sickle Cell Disease Burden with Novel Treatment Targets", Dana Farber Cancer Institute, Chicago, IL
- 11/2022 "Advancing in Curative Therapies for Sickle Cell Disease", Indian Society of Hematology and Transfusions, Kolkata, India
- 01/2023 "Updates on Curative Therapies for Thalassemia", HRSA Thalassemia Central Region ECHO Session, Virtual
- "Sickle Cell Disease", MDTI Lecture, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
- 02/2023 "Thalassemia and Sickle Cell Disease", Genetic Counseling Student Lecture, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA